Cytomegalovirus Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Alerts
• Clinical Trials
• Forums

A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Conditions:   Cytomegaloviral Infection;   Hematopoietic and Lymphoid System Neoplasm Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Biospecimen Collection;   Biological: CMV pp65 Peptide-loaded Alpha-type-1 Polarized Dendritic Cell Vaccine Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 21, 2022 Category: Research Source Type: clinical trials